@article{HortobagyiGranacherFernandezdelOlmoetal.2020,
  author    = {Hortobagyi, Tibor and Granacher, Urs and Fernandez-del-Olmo, Miguel and Howatson, Glyn and Manca, Andrea and Deriu, Franca and Taube, Wolfgang and Gruber, Markus and Marquez, Gonzalo and Lundbye-Jensen, Jesper and Colomer-Poveda, David},
  title     = {Functional relevance of resistance training-induced neuroplasticity in health and disease},
  series = {Neuroscience \& biobehavioral reviews : official journal of the International Behavioral Neuroscience Society},
  volume    = {122},
  journal   = {Neuroscience \& biobehavioral reviews : official journal of the International Behavioral Neuroscience Society},
  publisher = {Elsevier},
  address   = {Oxford},
  issn      = {0149-7634},
  doi       = {10.1016/j.neubiorev.2020.12.019},
  pages     = {79 -- 91},
  year      = {2020},
  abstract  = {Repetitive, monotonic, and effortful voluntary muscle contractions performed for just a few weeks, i.e., resistance training, can substantially increase maximal voluntary force in the practiced task and can also increase gross motor performance. The increase in motor performance is often accompanied by neuroplastic adaptations in the central nervous system. While historical data assigned functional relevance to such adaptations induced by resistance training, this claim has not yet been systematically and critically examined in the context of motor performance across the lifespan in health and disease. A review of muscle activation, brain and peripheral nerve stimulation, and imaging data revealed that increases in motor performance and neuroplasticity tend to be uncoupled, making a mechanistic link between neuroplasticity and motor performance inconclusive. We recommend new approaches, including causal mediation analytical and hypothesis-driven models to substantiate the functional relevance of resistance training-induced neuroplasticity in the improvements of gross motor function across the lifespan in health and disease.},
  language  = {en}
}
@article{ImeriFalleggerZivkovicetal.2014,
  author    = {Imeri, Faik and Fallegger, Daniel and Zivkovic, Aleksandra and Schwalm, Stephanie and Enzmann, Gaby and Blankenbach, Kira and Heringdorf, Dagmar Meyer Zu and Homann, Thomas and Kleuser, Burkhard and Pfeilschifter, Josef and Engelhardt, Britta and Stark, Holger and Huwiler, Andrea},
  title     = {Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice},
  series = {Neuropharmacology},
  volume    = {85},
  journal   = {Neuropharmacology},
  publisher = {Elsevier},
  address   = {Oxford},
  issn      = {0028-3908},
  doi       = {10.1016/j.neuropharm.2014.05.012},
  pages     = {314 -- 327},
  year      = {2014},
  abstract  = {The immunomodulatory FTY720 (fingolimod) is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that acts by modulating sphingosine 1-phosphate (S1P) receptor signaling. In this study, we have developed and characterized two novel oxazolo-oxazole derivatives of FTY720, ST-968 and the oxy analog ST-1071, which require no preceding activating phosphorylation, and proved to be active in intact cells and triggered S1P(1) and S1P(3), but not S1P(2), receptor internalization as a result of receptor activation. Functionally, ST-968 and ST-1071 acted similar to FTY720 to abrogate S1P-triggered chemotaxis of mouse splenocytes, mouse T cells and human U937 cells, and reduced TNFa- and LPS-stimulated endothelial cell permeability. The compounds also reduced TNF alpha-induced ICAM-1 and VCAM-1 mRNA expression, but restored TNF alpha-mediated downregulation of PECAM-1 mRNA expression. In an in vivo setting, the application of ST-968 or ST-1071 to mice resulted in a reduction of blood lymphocytes and significantly reduced the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice comparable to FTY720 either by prophylactic or therapeutic treatment. In parallel to the reduced clinical symptoms, infiltration of immune cells in the brain was strongly reduced, and in isolated tissues of brain and spinal cord, the mRNA and protein expressions of ICAM-1 and VCAM-1, as well as of matrix metalloproteinase-9 were reduced by all compounds, whereas PECAM-1 and tissue inhibitor of metalloproteinase TIMP-1 were upregulated. In summary, the data suggest that these novel butterfly derivatives of FTY720 could have considerable implication for future therapies of multiple sclerosis and other autoimmune diseases. (C) 2014 Elsevier Ltd. All rights reserved.},
  language  = {en}
}